CoreAge Rx NAD+ injection
CoreAge Rx lists NAD+ injectable at $93 a month, continuing. Medication is included in that catalog price. Readers comparing injectable NAD providers who need to verify the CoreAge Rx catalog edge before following its outbound path or reviewing the wider market. The commercial terms were checked 18 August 2026; state access, clinician approval, dispensing details, and personal suitability remain separate questions.

The short answer for this provider-treatment pair: CoreAge Rx NAD+ injection
Assess CoreAge Rx's NAD injection listing on its own route and commercial terms, without importing claims or pricing details from the provider's compounded GLP-1 and sermorelin programs.
Readers comparing injectable NAD providers who need to verify the CoreAge Rx catalog edge before following its outbound path or reviewing the wider market. A fair reading keeps CoreAge Rx's NAD+ injection listing separate from adjacent products that may use a related medication or sit in the same provider catalog.
Do not blur this product with adjacent options: NAD+ injectable
NAD+ injectable is cataloged as a compounded product in Subcutaneous injection format. FDA states that compounded drugs are not FDA-approved and do not receive the same premarket review as approved drug products. Ask for the exact formulation and dispensing pharmacy before purchase. That status is central to this CoreAge Rx guide because a related medication name does not make branded, compounded, oral, nasal, and injectable products interchangeable.
Subcutaneous injection is the exact format attached to CoreAge Rx's offer, while the canonical owner describes this comparison unit as Compounded NAD+ injection. Route matters for product identification, fulfillment, source selection, and a fair price comparison. This draft does not supply dose instructions, route conversions, or a claim that another formulation would have the same evidence, safety profile, convenience, or outcome.
The catalog-backed cost view: CoreAge Rx
CoreAge Rx's canonical offer lists NAD+ injectable at $93 a month, continuing. The number is computed from the same registry fields used by the treatment comparison, not copied into this draft as a fixed editorial amount. That connection matters because a future catalog correction can update the displayed commercial fact without leaving this guide on a stale, contradictory figure.
The canonical offer marks medication as included in the displayed price. It does not verify that labs, every consultation, supplies, expedited shipping, or future dose changes are included unless the source says so. Those items remain checkout questions. For CoreAge Rx NAD+ injection, read inclusion as one field in the offer record, not as proof that every service surrounding the prescription is free. The dated source establishes the advertised basis; it does not independently audit the final checkout, dispensing event, or quality of care.
Billing terms to settle before payment: CoreAge Rx NAD+ injection
The catalog records $93 a month, continuing. It does not establish every possible dose, renewal, refund, or future price. Confirm the complete checkout total and next billing date before payment. This is why Telehealth Ledger keeps introductory, recurring, upfront, effective-monthly, and commitment fields separate for CoreAge Rx's NAD+ injection offer. A monthly equivalent can be useful, but only when the required payment and term remain visible beside it.
The CoreAge Rx source for this edge was checked on 18 August 2026. Before paying for NAD+ injection, compare the amount charged today with the amount charged later, the number of months purchased, the renewal date, the cancellation window, and the refund boundary after clinical or pharmacy processing. A current catalog price cannot safely answer those policy questions unless the cited provider evidence does.
Coverage, eligibility, and fulfillment: NAD+ injection
The canonical record does not verify nationwide availability for this nad offer. An empty restriction list is not evidence of all-state coverage, so the page leaves state access unknown. The NAD+ injection access check belongs near the price because a low published figure has little decision value when CoreAge Rx cannot serve the reader's state or the selected product cannot be fulfilled there.
For CoreAge Rx NAD+ injection, the consumer brand, administrative platform, clinical group, and dispensing pharmacy can be different entities. A provider page may describe a national service while licensure, product rules, and pharmacy coverage narrow actual fulfillment. Ask which clinician entity would review the intake and which licensed pharmacy would dispense this exact product in the reader's state before treating access as settled.
What the provider dossier adds: CoreAge Rx
DSO Fine Shrimp d/b/a CoreAge Rx is recorded in the CoreAge Rx dossier as administrator. The site identifies this entity as the administrative platform. These entities can perform different jobs, so the consumer-facing brand should not automatically be described as the clinician or dispensing pharmacy for NAD+ injection.
Cancellation and renewal: The policy requires cancellation before renewal processing; exact plan timing needs checkout confirmation. The dossier also preserves this boundary for CoreAge Rx's NAD+ injection decision: Subscription language conflicts: The Help Center denies subscriptions while the refund policy discusses renewal and plan-dependent subscriptions. Carry that dated limitation into checkout instead of assuming a catalog price settles operations, fulfillment, or eligibility.
Use the broader owner for ranking: NAD+ injection
The linked NAD+ injection owner is the right place to rank CoreAge Rx beside other cataloged offers. Use the same fields for every row: continuing price, introductory period, required prepayment, medication inclusion, product type, delivery format, verification date, and state evidence. If two offers use different routes or one price excludes medication, a simple lowest-number verdict would not be a like-for-like conclusion.
From this CoreAge Rx guide, the comparison link resolves to the canonical NAD+ injection program owner, and the provider action uses the catalog's treatment-specific destination when one exists. Otherwise it uses the matching nad destination. That routing keeps the reader in the correct treatment lane and avoids sending a NAD+ injection decision to an unrelated offer.
When this offer belongs on the shortlist: CoreAge Rx NAD+ injection
CoreAge Rx's listing answers the basic commercial question for NAD+ injection, but it cannot answer personal eligibility, medical fit, pharmacy assignment, or an individual outcome. Those limits belong in the decision, not in fine print after it.
Readers comparing injectable NAD providers who need to verify the CoreAge Rx catalog edge before following its outbound path or reviewing the wider market. Treat the provider link as a verification step: confirm the product name, price phase, medication inclusion, state rule, pharmacy, renewal date, and refund boundary before payment.
CoreAge Rx NAD+ injection FAQ
- Which price belongs to this edge for CoreAge Rx NAD+ injection?
- The canonical catalog records $93 a month, continuing for NAD+ injectable, checked 18 August 2026. The amount should be read with any introduction, prepayment, or commitment shown in the same offer record. It is a dated published commercial fact, not a promise that every checkout configuration, future renewal, or product change will cost the same amount.
- Is medication part of that number in the CoreAge Rx figure?
- The canonical CoreAge Rx offer marks medication as included for NAD+ injection. That field does not automatically include labs, every consultation, supplies, faster shipping, dose-related price changes, or a future refill. Confirm those items and the complete charge in the selected checkout before treating the figure as all-inclusive.
- Can another route use these facts for CoreAge Rx NAD+ injection?
- This record is limited to NAD+ injectable in Subcutaneous injection format. It does not transfer price, regulatory status, evidence, convenience, dosing, pharmacy, or fulfillment claims to another NAD+ injection formulation or to a related product. Compare route and product identity before comparing the price because similar medication names can still describe materially different offers.
- Does an empty state list prove coverage for CoreAge Rx NAD+ injection?
- Nationwide availability is not verified in the canonical record. Confirm current state eligibility before relying on the offer. The state record is only one access field. CoreAge Rx must also confirm clinician licensure, product eligibility, and pharmacy fulfillment for the specific NAD+ injection prescription. Completing an intake does not guarantee approval, dispensing, or a particular outcome.
- Which page ranks alternatives for CoreAge Rx NAD+ injection?
- Use the canonical NAD+ injection program comparison. It reads current provider and price data from the registry and preserves the nad-injection treatment route. Compare CoreAge Rx only with offers that disclose the same price components, medication inclusion, commitment, and format; otherwise explain why the rows are not directly equivalent.
Sources and method
Telehealth Ledger checked provider pages, plan terms, and independent context on 18 August 2026. This page compares published commercial terms. It is not a rating, medical advice, or a guarantee that a clinician will prescribe treatment.
- CoreAge Rx NAD+ injection price source
- CoreAge Rx official website
- CoreAge Rx weight-loss pricing
- CoreAge Rx refund, return, and shipping policy
- CoreAge Rx terms of use
- CoreAge Rx Help Center
- CoreAge Rx pharmacy FAQ
- Trustpilot profile for coreagerx.com
- CoreAge Rx Reddit discussion
- FDA reminder on ingredients suitable for sterile compounding
- FDA questions and answers about drug compounding
- FDA overview of compounded-drug risks
